Skip to Content

Basaglar and Lantus - What is the difference between them?

Answers (1)

Official Answer by 9 Mar 2016

Basaglar is insulin glargine injection, approved in Dec 2015 and manufactured by Eli Lilly. Basaglar is a "follow-on" product to Lantus (insulin glargine injection), made by sanofi-aventis.

They are both long-acting human insulin analogues used for blood glucose (sugar) control in adult and pediatric patients with type 1 diabetes and in adults with type 2 diabetes.

Basaglar is administered subcutaneously once daily by the KwikPen at the same time every day.

The FDA does not consider Basaglar a biosimilar to Lantus. FDA did not approve Basaglar as a biosimilar to Lantus because Lantus was not approved under the Public Health Service Act, so there is no “reference product” for a proposed biosimilar product.

See more with our drug comparison tool:

Votes: +1 free discount card

Further Information

Search for questions

Still looking for answers? Try searching for what you seek or ask your own question.

Frequently Asked Questions

What type of drug is Motegrity?

Updated 16 days ago 1 answerFAQ by

What disease is Elzonris (tagraxofusp-erzs) used to treat?

Updated 13 days ago 1 answerFAQ by

How do you use the ProAir Digihaler?

Updated 13 days ago 1 answerFAQ by

How many biosimilars have been approved in the United States?

Updated 12 days ago 1 answerFAQ by